50% in seven days...

Watch this breakout 📈

April 23, 2025

Markets are waking up big this morning, and I’ve got my eye on a stock that’s been quietly ripping while most of the S&P has been sliding. It’s tied to a bold marketing play, some real momentum, and it still looks hungry. Worth a look if you’re hunting real momentum.

TODAY’S TOP ALERT! 

Mangoceuticals, Inc (Nasdaq: MGRX)

Happy Hump Day, Folks,

We’re halfway to the weekend and stock futures are looking very bright. ☀️

TSLA released miserable earnings after hours yesterday, with revenue down 20% year-over-year.

And yet, the stock is actually up a whopping $16+ in the pre-market thanks to Elon’s revelation that his time commitment to DOGE will drop “significantly” beginning in May.

Investors clearly think he’s the “indispensable man” and are excited he’s getting back to work.

Just proves that trying to use logic in this market may not be the best idea.  I prefer to follow strong price action instead.

It looks like there will be a lot of money pouring back into the markets today, and I’m hunting for trade ideas I think are likely to outperform the indexes.

I’m especially focused on one stock that’s had a more than 50% runup in the last 7 trading days (the S&P 500 is down about 2% from that point)...

Go ahead and pull up Mangoceuticals, Inc. (MGRX) on your favorite trading platform.

You’ll see the stock had an awesome rise to kick off the year, climbing nearly 150% into mid-February.

The stock stayed on a high plateau for more than a month before there was big selling pressure from late March through early April.

But beginning on April 11, the stock inflected back up and has been on an absolute tear.

It pulled back a bit to start this week and is now sitting at a level I think is worth a good look.

I’m watching MGRX today to see if it picks its momentum back up today.

👉  MGRX is TODAY’S #1 ALERT 👈

I first heard of MGRX on BarStool Sports’ popular “Only Stans” podcast. The company sponsored 8 episodes of the podcast, which reaches an average of 320,000 listeners per episode.

The company’s flagship product is a prescription medication for male “ED” issues called Mango 🥭, which uses the same active ingredients as the other two major drugs in the space.

You know what they are (the little “blue pill,” and the annoying commercials with couples holding hands in the bathtubs), but I won’t mention them here otherwise this email would go to your spam box!

But unlike those huge multi-billion dollar brands, whose marketing seems to target the elderly, Mango’s marketing seems to target younger, more sexually active audiences. Just a glance at the company’s website will show you what I mean.

In addition to the Barstool Sports show, the company has sponsored podcasts such as:

  • NoJumper and PlugTalk with Adam22

  • Pillow Talk with Ryan Pownall

  • Monday Morning Podcast with Bill Burr

  • Fly on the Wall with Dana Carvey and David Spade

  • The Dale Jr Podcast with Dale Earnhard Jr.

  • We’re Here To Help with Jake Johnson and Gareth Reynolds

That’s quite the lineup!

The company has also retained a marketing agency to help with social media advertising on Meta (Instagram/Facebook), Google, and YouTube.

You can check out this ad on YouTube for a sense of their… provocative advertising. As you can see, the video has gone viral (9.4 million views!) and is pretty darn funny.

In addition — and this is something I think is especially promising — the company has an affiliate marketing program whereby publishers and influencers can sign up at this website to access company-approved media, tools, and content to use on their own marketing platforms.

The marketing approach MGRX takes isn’t just arbitrary or cosmetic: The company has a special appeal to younger people…

A 2013 study found that ED affected 26% of men younger than 40, almost half of whom had severe ED. Obviously, there’s a social stigma associated with ED, and many men who have it find it embarrassing. That’s probably especially true for young men.

MGRX has a solution to at least help mitigate that concern: telemedicine. 

The company makes it simple to book an online telehealth visit, then medical providers in its medical network review and approve a prescription if medically appropriate.

At that point, the product then gets sent directly to the consumer — no awkward in-person doctor visit or pharmacy visit is necessary.

The company has expanded this model to offer a number of products popular for men’s health:

  • Grow - A product to treat hair loss that “combines two potent pharmaceutical-grade ingredients with two essential vitamins aimed to strengthen and nourish your hair from the inside out.”

  • Mojo - A “testosterone support protocol” that “offers an effective, safe, and convenient solution to boost your body’s own testosterone naturally.”

  • Prime - An “FDA-approved oral testosterone replacement therapy capsule.” The company explains: “Prime protocol simplifies testosterone therapy with access to board-certified physicians via telehealth appointments, blood kits shipped to your home, and an easy-to-take daily pill, eliminating the need for traditional office visits, pharmacy lines, and most importantly painful injections or topical applications.”

  • Slim - An oral dissolving tablet that combines vitamin B6 with Semaglutide, the active ingredient in Ozempic.

This last product is especially important. As I’m sure you know, the market for these weight-loss drugs is huge ($49.3 billion in 2024 and growing rapidly) and the company’s oral formulation is a huge advantage over the typical injections.

Another huge advantage is price. MGRX charges only $299/month for Slim, whereas Ozempic can be up to $1,000/month without insurance.

To expand its appeal, the company has launched the PeachesRX website to market Slim to women.

With a lower cost, telemedicine access, and needle-free delivery, Slim has clear advantages over its competitors. It launched only in October, so it will be very interesting to see how well it does.

The company is also pursuing new products such as Dermytol®, a skincare treatment targeting hyperpigmentation, and Diabetinol®, a plant-based nutraceutical to help improve metabolic health.

Conclusion

I have to be honest: I haven’t come across a small company this intriguing in a long time…

Between its dynamic, multi-pronged approach to marketing… its innovative use of telemedicine… and its now-expanding product line, I won’t be surprised if the stock has the … ahem… stamina to keep climbing.

At the very least, I think this stock deserves your sincere attention. My conclusions are my own, and you’ll have to make up your own mind.

As always, check out the stock’s chart, but with this company, I especially recommend checking out their main website, their corporate website, and their social media.

And of course, always approach your trading in a responsible manner, remembering that trading is very risky. Nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: MGRX has been on the move… up more than 50% over the past 7 trading days even after yesterday’s dip.

It’s a dynamic company with promising products, and I think it’s well worth looking at today.

Stay dialed in to MGRX today to see if its momentum continues!

To Your Success,

 

Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull

 

*Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.”

Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received twenty thousand dollars (cash) from Shore Thing Media for advertising Mangoceuticals, Inc for a one day marketing program on April 23, 2025. Previously, we were paid twelve thousand dollars from Bullzeye Media for advertising Mangoceuticals, Inc. from a period beginning on December 6 through December 7, 2023. It might seem obvious, but while our client claims not to own any shares in Mangoceuticals, Inc, whoever ultimately paid them most likely owns shares. You should assume they are looking to sell some or all of them at any time after we send out this information, which might negatively affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as the marketing campaign ends, though that is not always the case.

Now, diving right into Mangoceuticals, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies who are paying us and we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, 

Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1.ties br0ker-deale.r, br0ker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry auth.ority, or any self-regulat0ry organization.

So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture.